Rita Mehta, MD of UC Irvine Health discusses the MONARCH 2 trial and the use of abemaciclib and fulvestrant in advanced HR+/HER2 negative breast cancer progressing patients following prior endocrine therapy. This was recorded at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA.
Abstract 1000: MONARCH 2: Abemaciclib with Fulvestrant in Patients withs HR+/HER2-Advanced Breast Cancer who Progressed on Endocrine Therapy
Advertisement